Chief Executive Officer
CurrentAvery Therapeutics is developing first-in-class immunomodulatory therapeutics to redirect the immune system to address diseases of aging, inflammation, and fibrosis. Avery’s lead therapeutic program is under development to address heart failure, one of the leading causes of death in the world.